Cipla has introduced a new mobile application designed to assist in the first-line screening for asthma in India. The launch is part of the company's effort to address the significant burden of asthma in the country, which is estimated to affect around 34.3 million people, according to the Global Burden of Disease report. India has a notably higher asthma mortality rate—three times greater than the global average—and experiences a two-fold higher disability burden associated with asthma. These alarming statistics can be partly attributed to the underdiagnosis and undertreatment of the disease.
Umang Vohra, the Managing Director and Global CEO of Cipla, stated that the company is leveraging the latest technological advancements to develop solutions that are transforming patient care. These solutions aim to enhance diagnostic capabilities, improve treatment efficacy, and optimize asthma management outcomes, ultimately contributing to better quality of life for asthma patients in India.
The CipAir mobile app, initially available on Android devices, will enable users to assess their symptoms and receive guidance for further medical consultation. Cipla also plans to expand the availability of the app to iOS devices in the near future, making it more accessible to a wider audience